CagriSema, Novo Nordisk’s investigational once-weekly obesity injection, was associated with an average 25% body-weight loss after 68 weeks among 2,309 women with overweight or obesity in a post-hoc analysis of the phase 3 REDEFINE 1 trial, compared with 3% among women who received placebo, according to a report published by India Today on October 21, 2026. The drug — a fixed-dose combination of semaglutide and cagrilintide — remains investigational and is not approved or available as a treatment anywhere in the world.
The result matters to the peptide therapy and research peptide industry because it marks the first late-stage dataset to pair a GLP-1 receptor agonist with an amylin-pathway mimetic in a single weekly product, and because the same dataset contains a cautionary counter-signal: in a separate head-to-head phase 3 trial, CagriSema produced 23% weight loss after 84 weeks but failed to demonstrate non-inferiority to tirzepatide 15 mg. For clinics, telehealth operators, compounding pharmacies and peptide API suppliers, the news is less about a near-term product than about where dual-agonist demand, manufacturing capacity and regulatory scrutiny are heading.
What happened in the REDEFINE 1 post-hoc analysis
The 25% figure comes from a post-hoc analysis of REDEFINE 1, a phase 3 trial that enrolled more than 3,400 adults with overweight or obesity. Among the 2,309 women analysed, participants receiving CagriSema lost an average of 25% of body weight after 68 weeks, versus 3% in the placebo group, according to the India Today report.
A second post-hoc analysis examined outcomes by menopause stage, a period in which hormonal changes can contribute to weight gain and increased abdominal fat. Average weight loss was 26.7% among premenopausal women, 24.8% among perimenopausal women and 23.1% among postmenopausal women, the report states.
Novo Nordisk has cautioned that both analyses were conducted after the trial and are exploratory, requiring further investigation. The figures also reflect a trial efficacy measure that assumes participants remained on treatment, rather than a guarantee of the weight loss patients can expect in routine clinical practice. Subgroup sample sizes by menopause stage were not reported in the source material, and post-hoc subgroup findings are generally vulnerable to confounding by age, body composition and baseline characteristics.
The key numbers: CagriSema versus semaglutide and tirzepatide
The headline 25% figure sits above the overall REDEFINE 1 result. In the full trial, CagriSema produced an average weight loss of 22.7% after 68 weeks — below Novo Nordisk’s own 25% target. The women-only post-hoc analysis therefore describes a subgroup that outperformed the trial average, a distinction that matters when the number is quoted in isolation.
| Measure | Result | Context |
|---|---|---|
| CagriSema, women in REDEFINE 1 (post-hoc) | 25% average weight loss at 68 weeks | n=2,309; placebo 3% |
| CagriSema, overall REDEFINE 1 | 22.7% at 68 weeks | Below Novo Nordisk’s 25% target |
| CagriSema by menopause stage (post-hoc) | 26.7% premenopausal; 24.8% perimenopausal; 23.1% postmenopausal | Exploratory subgroup analysis |
| CagriSema vs tirzepatide 15 mg (head-to-head) | 23% at 84 weeks; non-inferiority not demonstrated | Separate phase 3 trial |
| Semaglutide 2.4 mg (cross-trial) | ~15% weight reduction | Major obesity trials; not head-to-head |
| Higher-dose tirzepatide (cross-trial) | ~20% weight reduction | Pivotal trial; not head-to-head |
The comparison figures of roughly 15% for semaglutide 2.4 mg and around 20% for higher-dose tirzepatide come from cross-trial comparisons, which the source report explicitly notes are not direct evidence that one drug is superior. Trial populations, durations, dose escalation schedules and background lifestyle interventions differ, and none of those figures should be read as a like-for-like ranking.
Why it matters for peptide therapy and research peptide supply chains
CagriSema combines semaglutide, a GLP-1 receptor agonist available as both injectable and oral formulations for different approved uses, with cagrilintide, which mimics the appetite-regulating hormone amylin. The once-weekly injection targets two separate pathways involved in appetite and food intake. Tirzepatide, marketed in India under brands including Mounjaro and Yurpeak, takes a different dual approach, acting on both GLP-1 and GIP receptors.
For the peptide supply chain, the practical significance lies in complexity rather than in the headline percentage. A fixed-dose combination of two peptides requires two independent API streams, two sets of impurity profiles, and a formulation that keeps both molecules stable in one container closure system over shelf life. Each additional peptide in a device multiplies the analytical work: identity and assay for both actives, related-substance profiling for each, and container-closure and compatibility testing for the finished combination product. This is the kind of programme that strains contract development and manufacturing capacity well before it reaches a clinic shelf.
Industry observers note that demand signals of this kind tend to move through the market in a predictable order: first research-peptide suppliers see inquiry volume rise for the individual molecules, then compounding and telehealth channels field patient questions about combination approaches, and only later does any approved product reach prescribers. That sequence creates a compliance gap, because a research-use-only peptide is not a medicine and a compounded preparation is not an FDA-approved product. Peptide therapy clinics evaluating any dual-agonist enquiry should confirm the regulatory status of the specific molecule, formulation and supplier before discussing treatment options with patients.
Quality documentation is the practical control point. A batch certificate of analysis reports specified results for a material or batch, but it does not by itself establish clinical safety, efficacy, sterility for a particular use, or regulatory approval. Buyers assessing peptide API or finished vials should request the full identity, purity, assay and impurity package, and should treat chromatographic purity percentages as method-dependent rather than as a statement of content by weight. For background on how these categories differ, peptidescm maintains reference material on peptide API and finished-drug distinctions.
Research and market context: what the head-to-head result changes
The most consequential number in the dataset may not be 25% at all. In the separate head-to-head phase 3 trial, CagriSema produced 23% weight loss after 84 weeks but failed to demonstrate non-inferiority to tirzepatide 15 mg. That is a direct comparison, and it undercuts any reading of the cross-trial figures as evidence of superiority. The reasons for the non-inferiority failure — dose selection, trial duration, population differences or other factors — were not given in the source material and remain an open question.
This distinction matters commercially. Markets including India have absorbed injectable semaglutide and tirzepatide at scale, and the prospect of a more potent option has been framed as a potential shift in that landscape. But a drug that has not cleared a head-to-head bar against the incumbent, and that is unapproved everywhere, is a pipeline asset rather than a market entrant. Clinics and telehealth platforms planning formulary or service expansion should treat launch timing, pricing and approved indications as unknown variables.
For research-peptide businesses, the more durable signal is methodological. Dual- and triple-pathway incretin analogues are now a defined research direction, and the analytical expectations that come with them — orthogonal methods such as HPLC for separation and LC-MS for molecular-mass confirmation and impurity characterisation — are becoming baseline rather than premium. Suppliers that can document method suitability, batch traceability and stability data for each active will be better positioned as inquiry volume grows, regardless of whether any single candidate is approved.
What comes next
Three things are worth watching. First, whether Novo Nordisk advances CagriSema into regulatory submission and what the full REDEFINE 1 and head-to-head datasets show once published in peer-reviewed form, including subgroup sizes and discontinuation handling. Second, whether the exploratory menopause-stage findings hold up in prespecified analyses, since post-hoc subgroup results frequently attenuate on replication. Third, how compounding and telehealth channels respond to patient demand for combination incretin approaches before any approval exists — an area where prescription requirements, medical supervision and jurisdictional rules apply and where research-use labelling does not substitute for regulatory authorisation.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. PeptideSCM as a provider in the industry domain tracks API sourcing, fill-finish capacity and cold-chain logistics questions that follow pipeline news of this kind.
Frequently asked questions
Is CagriSema approved for weight loss?
No. CagriSema is investigational and is not an approved or available treatment option anywhere in the world, according to the source report. Any clinical use would require regulatory approval and, where applicable, a prescription and medical supervision.
How does the 25% figure compare with semaglutide and tirzepatide?
Cross-trial figures cited in the report are roughly 15% weight reduction with semaglutide 2.4 mg in major obesity trials and around 20% with higher-dose tirzepatide in its pivotal trial. These are cross-trial comparisons, not direct evidence of superiority, and the separate head-to-head trial did not show CagriSema non-inferior to tirzepatide 15 mg.
What is the difference between CagriSema and tirzepatide?
CagriSema pairs semaglutide, a GLP-1 receptor agonist, with cagrilintide, an amylin-pathway mimetic. Tirzepatide acts on both GLP-1 and GIP receptors. The approved products, indications, dosing and labelling differ, and medical decisions should rest on the relevant product labelling and professional evaluation.
Does the 25% result apply to routine clinical practice?
Not directly. The figures come from a post-hoc analysis under a trial efficacy measure that assumes participants remained on treatment. Novo Nordisk has described the analyses as exploratory and requiring further investigation.
Comments